Pharming posts positive leniolisib Phase II topline data in PIDs
Pharming said a late-breaking ESID 2026 abstract will highlight positive Phase II topline data for leniolisib in primary immunodeficiencies with immune dysregulation.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.